Bayer Advia Centaur Ca 19-9 Assay
FDA 510(k) K031393 · Bayer Healthcare, LLC
Submission
- Device name
- Bayer Advia Centaur Ca 19-9 Assay
- Applicant
- Bayer Healthcare, LLC
Tarrytown, NY, US - Received
- May 2, 2003
- Decision date
- June 24, 2003
- Decision
- Substantially Equivalent (SESE)
- Type
- Traditional 510(k)
- Summary
- 510(k) summary available from FDA
Device classification
- Product code
- NIG – System, Test, Carbohydrate Antigen (Ca19-9), For Monitoring And Management Of Pancreatic Cancer
- Device class
- Class II (moderate risk)
- Regulation
- 21 CFR 866.6010
- Specialty
- Immunology
An in vitro diagnostic test for the quantitative measurement of the CA 19-9 tumor associated antigen in human serum or plasma. The test is intended as an aid in the management of patients with confirmed pancreatic cancer and serial monitoring of their response to therapy and disease progression. The test should only be used in patients with serum and plasma CA 19-9 values above the cut-off at…
Other 510(k)s with product code NIG
| 510(k) | Device | Applicant | Decision |
|---|---|---|---|
| K253528 | Atellica IM CA 19-9 IINIG · Traditional | Siemens Healthcare Diagnostics, Inc. | 08/10/2026SE |
| K231525 | VITROS Immunodiagnostic Products CA 19-9TM Reagent PackNIG · Traditional | Ortho Clinical Diagnostics | 08/09/2023SE |
| K200997 | Lumipulse G CA19-9-NNIG · Special | Fujirebio Diagnostics,Inc. | 05/14/2020SE |
| K191973 | Lumpipulse G CA19-9-NNIG · Traditional | Fujirebio Dianostics, Inc. | 10/22/2019SE |
| K100375 | Dimension Vista Loci Ca 19-9 Flex Reagent Cartridge, and Dimension LOCI7 Calibrator with…NIG · Traditional | Siemens Healthcare Diagnostics, Inc. | 04/06/2011SE |
| K052889 | Vitros Ca 19-9NIG · Traditional | Fujirebio Diagnostics,Inc. | 12/20/2005SE |
| K052000 | Architect Ca 19-9XR AssayNIG · Traditional | Fujirebio Diagnostics,Inc. | 10/25/2005SE |
| K033038 | Gi Monitor and Gi Monitor Calibrators on the Access Immunoassay Systems, Model 387687…NIG · Traditional | Beckman Coulter, Inc. | 12/29/2003SE |
| K023240 | ST Aia-Pack Ca 19-9NIG · Traditional | Tosoh Corp. | 12/23/2002SE |
| K023239 | Aia-Pack Ca 19-9NIG · Traditional | Tosoh Corp. | 12/23/2002SE |
More from Tosoh Corp.
| 510(k) | Device | Decision |
|---|---|---|
| K171802 | ALEVE Direct Therapy (ALEVE Direct Therapy TENS Device)NUH · Traditional | 03/07/2018SE |
| K152852 | ALEVE Direct Therapy (ALEVE Direct Therapy TENS device)NUH · Traditional | 12/22/2015SE |
| K150942 | Contour Next USB Blood Glucose Monitoring SystemNBW · Special | 11/25/2015SE |
| K151742 | Contour Next Control SolutionJJX · Traditional | 09/23/2015SE |
| K130265 | Contour Next Ez Blood Glucose MeterNBW · Traditional | 06/23/2014SE |
| K122370 | Contour Next Link Wireless Blood Glucose MonitorNBW · Traditional | 09/26/2013SE |
| K121190 | Contour Next Blood Glucose MeterLFR · Special | 07/26/2012SE |
| K121087 | Contour Next Usb Blood Glucose Monitoring SystemNBW · Special | 06/28/2012SE |
| K110894 | Contour Next Link Wireless Blood Glucose MeterLFR · Traditional | 03/28/2012SE |
| K110587 | Contour Link Blood Glucose Meter, Contour Blood Glucose Test Strips, Contour Control…LFR · Traditional | 03/28/2012SE |
Questions and answers
When was Bayer Advia Centaur Ca 19-9 Assay cleared by the FDA?
Bayer Advia Centaur Ca 19-9 Assay (K031393) received a 510(k) decision of Substantially Equivalent on June 24, 2003, 53 days after the submission was received.
What is the product code of K031393?
The FDA product code is NIG – System, Test, Carbohydrate Antigen (Ca19-9), For Monitoring And Management Of Pancreatic Cancer, a Class II (moderate risk) device regulated under 21 CFR 866.6010.